J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $250.68
    +6.14 (+2.51%)

    Market Cap: $15.87B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(25/40)
    Avg Surprise
    +0.43%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$6.47
    Range$5.81 - $7.11
    17 analysts
    EPS Revisions
    11
    0
    7d
    9
    5
    30d
    EPS Estimate Drift
    90d ago$6.36-1.7%
    60d ago$6.39-1.3%
    30d ago$6.37-1.5%
    7d ago$6.49+0.3%
    Current$6.47
    Revenue Consensus
    $1.2B
    Range$1.2B - $1.2B
    16 analysts
    Dec 31, 2026
    EPS Consensus$7.73
    Range$6.69 - $9.59
    16 analysts
    Revenue Consensus
    $1.4B
    Range$1.4B - $1.5B
    18 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$7.73---
    Sep 26EST
    		-$6.47---
    Jun 26
    		$4.89$5.06-3.36%Miss+159.3%
    Mar 26
    		$6.34$4.66+36.05%Beat+277.4%
    Dec 25
    		$6.64$6.51+2.05%Beat+0.6%
    Sep 25
    		$6.99$4.80+45.63%Beat+5.7%
    Jun 25
    		$-8.25$-6.25-32.00%Miss-255.7%
    Mar 25
    		$1.68N/A-63.95%Miss-37.3%
    Dec 24
    		$6.60$5.81+13.58%Beat+31.5%
    Sep 24
    		$6.61$5.50+20.18%Beat+36.6%
    Jun 24
    		$5.30$4.78+10.88%Beat+17.5%
    Mar 24
    		$2.68$4.18-35.89%Miss-32.2%
    Dec 23
    		$5.02$5.18-3.09%Miss+7271.4%
    Sep 23
    		$4.84$4.93-1.83%Miss-6.4%
    Jun 23
    		$4.51$4.43+1.81%Beat+4.9%
    Mar 23
    		$3.95$4.22-6.40%Miss+5.9%
    Dec 22
    		$-0.07N/A-121.88%Miss-101.7%
    Sep 22
    		$5.17$4.67+10.71%Beat+23.1%
    Jun 22
    		$4.30$4.19+2.63%Beat+10.3%
    Mar 22
    		$3.73$3.89-4.11%Miss-4.8%
    Dec 21
    		$4.21$3.64+15.66%Beat+5.2%
    Sep 21
    		$4.20$3.31+26.89%Beat-2.6%
    Jun 21
    		$3.90$3.45+13.04%Beat+5.1%
    Mar 21
    		$3.92$3.73+5.09%Beat+771.1%
    Dec 20
    		$4.00$4.20-4.76%Miss-9.5%
    Sep 20
    		$4.31$4.08+5.64%Beat+5.1%
    Jun 20
    		$3.71$3.11+19.29%Beat-8.4%
    Mar 20
    		$0.45$0.67-32.84%Miss-87.7%
    Dec 19
    		$4.42$4.12+7.28%Beat+21.4%
    Sep 19
    		$4.10$3.59+14.21%Beat+14.5%
    Jun 19
    		$4.05$3.57+13.45%Beat+16.0%
    Mar 19
    		$3.67$3.16+16.14%Beat+23.2%
    Dec 18
    		$3.64$3.02+20.53%Beat+23.4%
    Sep 18
    		$3.58$3.32+7.83%Beat+11.2%
    Jun 18
    		$3.49$3.21+8.72%Beat+36.3%
    Mar 18
    		$2.98$2.78+7.19%Beat+29.0%
    Dec 17
    		$2.95$2.98-1.01%Miss+8.9%
    Sep 17
    		$3.22$2.89+11.42%Beat+25.3%
    Jun 17
    		$2.56$2.75-6.91%Miss-
    Mar 17
    		$2.31$2.34-1.28%Miss-
    Dec 16
    		$2.71$2.65+2.26%Beat-
    Sep 16
    		$2.57$2.61-1.53%Miss-

    Key Metrics

    Valuation
    P/E Ratio10.08EV/EBITDA11.45x
    Price/FCF10.46xFCF Yield9.56%
    Profitability
    Profit Margin20.40%Operating Margin26.90%
    ROE22.10%ROIC9.82%
    Financial Health
    Debt/Equity0.91xInterest Coverage5.31x
    Current Ratio1.78xQuick Ratio1.58x
    Trading Statistics
    Beta0.36Avg Volume1.12M
    52-Week High$266.3852-Week Low$123.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$251.85
    SMA 20$252.38
    SMA 50$247.45
    SMA 200$203.54
    EMA 10$250.91
    EMA 20$251.10
    EMA 50$246.05
    EMA 200$208.67

    MACD

    Line: 0.47Signal: 1.27Hist: -0.80

    ADX

    ADX: 14.2+DI: 20.9-DI: 22.8

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down56.0
    PSAR$266.38

    Bollinger Bands

    Upper Band$262.91
    Lower Band$241.84
    %B Position835%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    50.2

    Momentum Oscillators

    Stoch %K31.6
    Stoch %D37.2
    Williams %R-61.0
    ROC (10d)0.9%
    Momentum2.32
    CCI (20d)-68.3
    MFI (14d)34.0

    Volatility Measures

    ATR (14d)$7.76(3.1%)
    StdDev (20d)5.27
    Hist Vol32.9%(Moderate)

    Volume Flow

    VWAP$248.26
    OBV34.7M
    AD Line19.7M
    CMF (20d)0.002

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.1x
    VWMA (20d)$252.67

    Pivot Points

    R3$254.77
    R2$252.71
    R1$248.62
    Pivot Point$246.56
    S1$242.47
    S2$240.41
    S3$236.32

    Advanced Oscillators

    TSI1.98
    Ultimate Osc50.5
    KST5.64

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.21B$1.07B$1.20B$1.13B$1.05B$897.80M$1.09B$1.05B$1.02B$901.98M$1.01B$972.14M
    Cost of Revenue$116.40M$134.10M$153.53M$128.88M$116.30M$104.60M$128.71M$111.61M$109.90M$95.49M$107.24M$102.15M
    Gross Profit$1.09B$934.80M$1.04B$997.23M$929.40M$793.20M$959.46M$943.36M$913.92M$806.50M$904.69M$869.99M
    Operating Expenses$843.70M$598.20M$789.86M$939.72M$1.62B$849.10M$768.69M$683.15M$714.48M$740.29M$782.20M$697.60M
    R&D$284.50M$196.00M$213.91M$240.70M$1.10B$180.70M$240.50M$199.92M$220.73M$232.85M$234.61M$234.40M
    SG&A$389.20M$352.70M$406.21M$530.65M$358.40M$514.00M$369.29M$325.77M$338.52M$351.71M$396.03M$308.31M
    Operating Income$248.20M$336.60M$254.53M$57.51M$-686,400,000$-55,900,000$190.77M$260.21M$199.44M$66.21M$122.50M$172.39M
    Interest Income$-37,100,000$-39,900,000$-45,406,000$-48,576,000$-47,400,000$-53,700,000$-51,256,000$-58,702,000$-62,023,000$-66,116,000$-70,324,000$-71,497,000
    Interest Expense$37.20M$37.40M$46.06M$48.47M$49.20M$53.90M$57.55M$59.40M$61.52M$67.81M$60.97M$72.87M
    Income Before Tax$211.00M$299.20M$208.47M$9.04M$-735,600,000$-109,800,000$133.22M$200.81M$137.93M$-1,602,000$61.53M$99.52M
    Income Tax Expense$18.10M$6.10M$4.96M$-242,424,000$-17,200,000$-17,800,000$-57,912,000$-14,533,000$-30,653,000$11.67M$-33,089,000$-47,176,000
    Net Income$192.80M$293.10M$203.45M$251.41M$-718,500,000$-92,500,000$191.12M$215.06M$168.57M$-14,618,000$94.15M$146.82M
    EBITDA$427.20M$520.50M$433.05M$235.86M$-514,200,000$108.70M$352.89M$424.74M$362.99M$227.90M$291.05M$333.57M
    EBIT$248.10M$339.10M$253.88M$57.61M$-688,200,000$-56,100,000$184.47M$259.51M$199.95M$64.51M$131.85M$171.01M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JAZZ

    Government Contracts

    Gov Obligations (TTM)
    $176384
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    -92.0%
    Active Awards
    18
    New Awards (TTM)
    6
    Avg Remaining Term
    1.9 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0146Department of Veterans AffairsDepartment of Veterans Affairs$397859Feb 1, 2026
    36C26026F0013Department of Veterans AffairsDepartment of Veterans Affairs$231127Oct 1, 2025
    36C26026F0012Department of Veterans AffairsDepartment of Veterans Affairs$133028Oct 1, 2025
    36C24526N0282Department of Veterans AffairsDepartment of Veterans Affairs$14672Jan 31, 2026
    36C24526N0198Department of Veterans AffairsDepartment of Veterans Affairs$14243Dec 23, 2025
    36C26026F0027Department of Veterans AffairsDepartment of Veterans Affairs$0Oct 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Jazz Pharmaceuticals stock hits all-time high at 265.54 USD

    Jazz Pharmaceuticals PLC's stock reached an all-time high of $265.54, marking a 109.94% increase over the past year. The company, valued at $17.09 billion, is considered undervalued by InvestingPro analysis despite beating revenue expectations in the second quarter. Analyst firms have raised their price targets for JAZZ, citing strong performance in its diversified portfolio and key products.

    Investing.com•8/25/26•
    Neutral

    Jazz Pharmaceuticals stock hits all-time high at 265.54 USD By Investing.com

    Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $265.54, marking a 109.94% increase over the past year. The company, valued at $17.09 billion, has a P/E ratio of 17.68 and is considered undervalued by InvestingPro. Analysts have revised earnings upwards, and the company reported strong Q2 revenue, although EPS fell short due to dilution and R&D expenses.

    Investing.com Canada•8/25/26•
    Bullish

    Jazz stock gains on FDA nod for cancer therapy (JAZZ:NASDAQ)

    Jazz Pharmaceuticals (JAZZ) stock gained after the company announced FDA approval for two regimens containing its cancer therapy, Ziihera. The therapy was developed in collaboration with BeOne Medicines (ONC) and under licensing deals from Zymeworks (ZYME). This approval marks a significant development for the Irish biopharma company and its partners.

    Seeking Alpha•8/25/26•
    Bullish

    Jazz Pharma's fresh tune: New CEO wants to make longtime Bay Area drugmaker 'a true innovator'

    Renee Gala is set to become the new CEO of Jazz Pharmaceuticals on August 11. Her goal is to transform the longtime Bay Area drugmaker into a true innovator. A year into her tenure, the company anticipates a potential new drug approval for a product licensed under the previous leadership.

    The Business Journals•8/24/26•
    Somewhat-Bullish

    Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ

    Advisors Preferred LLC recently acquired a new stake of 20,861 shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), valued at approximately $5.079 million. Other institutional investors have also adjusted their positions in the company, which saw its stock open at $248.70 with a market cap of $16.15 billion. The pharmaceutical company recently missed analysts' consensus earnings estimates but reported a 15.5% increase in revenue year-over-year.

    MarketBeat•8/21/26•
    Neutral

    Frequently Asked Questions About JAZZ

    Does JAZZ pay dividends?
    Jazz Pharmaceuticals PLC (JAZZ) does not currently pay a regular dividend.
    What is JAZZ's P/E ratio?
    Jazz Pharmaceuticals PLC has a price-to-earnings (P/E) ratio of 10.08.
    What is JAZZ's market cap?
    Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $15.87B with a current stock price of $250.68.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In